Cargando…

Survival outcomes after synchronous para‐aortic lymph node metastasis in colorectal cancer: A systematic review

BACKGROUND: Synchronous para‐aortic lymph node metastasis (PALNM) in colorectal cancer (CRC) is a relatively rare clinical entity. There is a lack of consensus on management of these patients, and the role of para‐aortic lymph node dissection (PALND) remains controversial. This systematic review aim...

Descripción completa

Detalles Bibliográficos
Autores principales: Aylward, Conor, Noori, Jawed, Tyrrell, Jack, O'sullivan, Niall, Kavanagh, Dara O., Larkin, John O., Mehigan, Brian J., McCormick, Paul H., Kelly, Michael E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10100040/
https://www.ncbi.nlm.nih.gov/pubmed/36350234
http://dx.doi.org/10.1002/jso.27139
Descripción
Sumario:BACKGROUND: Synchronous para‐aortic lymph node metastasis (PALNM) in colorectal cancer (CRC) is a relatively rare clinical entity. There is a lack of consensus on management of these patients, and the role of para‐aortic lymph node dissection (PALND) remains controversial. This systematic review aims to describe the survival outcomes in colorectal cancer with synchronous PALNM when lymph node dissection is performed. METHODS: A systematic review of Pubmed, Embase and Web of Science databases for PALND in CRC was performed. Studies including patients with synchronous PALNM undergoing resection with curative intent, published from the year 2000 onwards, were included. RESULTS: Twelve retrospective studies were included. Four studies reported survival outcomes for rectal cancer, two for colon cancer and six as colorectal. Survival outcomes for 356 patients were included. Average 5‐year overall survival (OS) was 22.4%, 33.9% and 37.7% in the rectal, colon and colorectal groups respectively. Three year OS in the groups was 53.6%, 46.2% and 65.7%. CONCLUSION: There remains a lack of quality data to confidently make recommendations regarding the management of synchronous PALNM in colon and rectal cancer cohorts. Retrospective data suggests a benefit in highly selective cohorts and therefore a case‐by‐case evaluation remains the standard of care.